Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC

The study enrolled patients with advanced or metastatic NSCLC harboring HER2 mutations, amplification, or overexpression who had progressed after ≥1 prior lines of anticancer therapy. After enrollment, participants received treatment with rezetamab plus pertuzumab until disease progression, intolerable toxicity, withdrawal of consent, or other conditions requiring treatment discontinuation.

NCT Number	NCT07377916
Lead Sponsor	The First Affiliated Hospital of Guangzhou Medical University Collaborators: Maoming People's Hospital, Peking University Shenzhen Hospital
Conditions	Non-Small Cell Lung Cancer
Enrollment	60 participants
Start Date	2026-02-15
Primary Completion	2029-06-30 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-30